EMA proposes 10 recommendations to unlock potential of big dataEuropean regulators have proposed ten recommendations that aim to unlock the potential of big data for public health Share XEMA proposes 10 recommendations to unlock potential of big datahttps://pharmaphorum.com/news/ema-proposes-10-recommendations-to-unlock-potential-of-big-data/
EMA counts the cost of Brexit in lost staff and narrower workloadThe EMA’s forced move from London to Amsterdam in the wake of the UK’s decision to leave the Share XEMA counts the cost of Brexit in lost staff and narrower workloadhttps://pharmaphorum.com/news/ema-counts-the-cost-of-brexit-in-lost-staff-and-narrower-workload/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
EMA resolves dispute over pricey Canary Wharf tenancyAfter months of wrangling, the EMA finally has a solution to the £500 million financial liability it has Share XEMA resolves dispute over pricey Canary Wharf tenancyhttps://pharmaphorum.com/news/ema-resolves-dispute-over-pricey-canary-wharf-tenancy/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
Mitsubishi Tanabe pulls ALS drug from EMA assessmentMitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements Share XMitsubishi Tanabe pulls ALS drug from EMA assessmenthttps://pharmaphorum.com/news/mitsubishi-tanabe-pulls-als-drug-from-ema-assessment/
EMA set for official move from London on 1 MarchThe European Medicines Agency (EMA) has officially taken over its new building in Amsterdam in preparation of its Share XEMA set for official move from London on 1 Marchhttps://pharmaphorum.com/news/ema-set-official-move-london/
UK drugs regulator consults on ‘no deal’ Brexit arrangementsDespite the government insisting that Brexit will have no negative fallout, the UK’s drugs regulator is consulting on Share XUK drugs regulator consults on ‘no deal’ Brexit arrangementshttps://pharmaphorum.com/news/uk-drugs-regulator-consults-on-no-deal-brexit-arrangements/
Europe’s CHMP regulatory committee has new chairEurope’s top drugs regulatory committee has a new leader after Dr Tomas Salmonson stepped down as chair of Share XEurope’s CHMP regulatory committee has new chairhttps://pharmaphorum.com/news/europes-chmp-regulatory-committee-has-new-chair/
